Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years who have been diagnosed with a specific type of scarring lung disease (fibrosing ILD) — specifically one linked to a connective tissue disorder, a condition called fibrotic hypersensitivity pneumonitis, or a non-IPF type of scarring lung disease — confirmed by a central review panel
• People whose diagnosing doctor at the trial site has confirmed a diagnosis of fibrotic ILD
• People who are willing to follow the study procedures and attend follow-up visits
• People who are willing to provide written consent to participate

Who may not be able to join:

• People whose scarring lung disease was first diagnosed more than 5 years before the initial screening visit
• People whose lung scans show only very minor scarring, affecting less than 5% of the lung, without more significant structural changes (confirm with trial site)
• People whose lung scans show a large amount of emphysema (air trapping/lung damage) — specifically more than 15% of total lung volume, or more emphysema than scarring (confirm with trial site)
• People who have had an active cancer in the past year, with the exception of certain non-melanoma skin cancers treated locally
• People who are unable to complete a full breathing/lung function test at the screening visit
• People who are currently taking the medications nintedanib or nerandomilast at the time of the screening visit
• People who are pregnant at the time of screening, or who plan to become pregnant during the study
• People who are currently in another interventional clinical trial for scarring lung disease, or who have received an experimental drug within the 4 weeks before the screening visit (or longer, depending on the drug)

Important: Always verify eligibility with the trial site directly before applying.